Analysts’ Recent Ratings Updates for Definium Therapeutics (DFTX)

A number of research firms have changed their ratings and price targets for Definium Therapeutics (NASDAQ: DFTX):

• 7/8/2026 – Definium Therapeutics had its price target raised by Stifel Nicolaus from $30.00 to $60.00. They now have a “buy” rating on the stock.
• 7/4/2026 – Definium Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/30/2026 – Definium Therapeutics was given a new $58.00 price target by Canaccord Genuity Group Inc.. They now have a “buy” rating on the stock.
• 6/24/2026 – Definium Therapeutics had its price target raised by JonesTrading from $61.00 to $74.00. They now have a “buy” rating on the stock.
• 6/23/2026 – Definium Therapeutics had its price target raised by Robert W. Baird from $37.00 to $57.00. They now have an “outperform” rating on the stock.
• 6/23/2026 – Definium Therapeutics had its price target raised by Needham & Company LLC from $38.00 to $50.00. They now have a “buy” rating on the stock.
• 6/22/2026 – Definium Therapeutics had its “buy” rating reaffirmed by Citigroup Inc..
• 6/22/2026 – Definium Therapeutics was given a new $60.00 price target by Canaccord Genuity Group Inc..
• 6/22/2026 – Definium Therapeutics was given a new $60.00 price target by Oppenheimer Holdings, Inc.. They now have an “outperform” rating on the stock.
• 6/22/2026 – Definium Therapeutics had its “outperform” rating reaffirmed by Royal Bank Of Canada.
• 6/22/2026 – Definium Therapeutics was given a new $52.00 price target by Leerink Partners. They now have an “outperform” rating on the stock.
• 6/16/2026 – Definium Therapeutics had its “buy” rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $38.00 price target on the stock.

Insider Buying and Selling

In other news, CEO Robert Barrow sold 29,208 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $1,315,236.24. Following the completion of the sale, the chief executive officer owned 1,098,246 shares in the company, valued at approximately $49,454,017.38. This trade represents a 2.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Matthew T. Wiley sold 2,867 shares of Definium Therapeutics stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $129,101.01. Following the completion of the sale, the insider directly owned 174,633 shares in the company, valued at approximately $7,863,723.99. The trade was a 1.62% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 48,096 shares of company stock worth $2,165,763. Insiders own 2.40% of the company’s stock.

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.